JP2023116697A5 - - Google Patents

Download PDF

Info

Publication number
JP2023116697A5
JP2023116697A5 JP2023097964A JP2023097964A JP2023116697A5 JP 2023116697 A5 JP2023116697 A5 JP 2023116697A5 JP 2023097964 A JP2023097964 A JP 2023097964A JP 2023097964 A JP2023097964 A JP 2023097964A JP 2023116697 A5 JP2023116697 A5 JP 2023116697A5
Authority
JP
Japan
Prior art keywords
human
weight gain
agent
use according
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023097964A
Other languages
English (en)
Japanese (ja)
Other versions
JP7755618B2 (ja
JP2023116697A (ja
Filing date
Publication date
Priority claimed from JP2021525049A external-priority patent/JP7432598B2/ja
Application filed filed Critical
Priority to JP2023097964A priority Critical patent/JP7755618B2/ja
Publication of JP2023116697A publication Critical patent/JP2023116697A/ja
Publication of JP2023116697A5 publication Critical patent/JP2023116697A5/ja
Application granted granted Critical
Publication of JP7755618B2 publication Critical patent/JP7755618B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023097964A 2018-11-05 2023-06-14 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法 Active JP7755618B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023097964A JP7755618B2 (ja) 2018-11-05 2023-06-14 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021525049A JP7432598B2 (ja) 2018-11-05 2018-11-05 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法
PCT/GB2018/053203 WO2020095010A1 (en) 2018-11-05 2018-11-05 Methods of treating diabetes in severe insulin-resistant diabetic subjects
JP2023097964A JP7755618B2 (ja) 2018-11-05 2023-06-14 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021525049A Division JP7432598B2 (ja) 2018-11-05 2018-11-05 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法

Publications (3)

Publication Number Publication Date
JP2023116697A JP2023116697A (ja) 2023-08-22
JP2023116697A5 true JP2023116697A5 (https=) 2024-05-27
JP7755618B2 JP7755618B2 (ja) 2025-10-16

Family

ID=64332106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525049A Active JP7432598B2 (ja) 2018-11-05 2018-11-05 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法
JP2023097964A Active JP7755618B2 (ja) 2018-11-05 2023-06-14 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021525049A Active JP7432598B2 (ja) 2018-11-05 2018-11-05 重度のインスリン抵抗性糖尿病の対象における糖尿病の治療方法

Country Status (5)

Country Link
US (1) US20220023269A1 (https=)
JP (2) JP7432598B2 (https=)
AU (2) AU2018448511B2 (https=)
CA (1) CA3118629A1 (https=)
WO (1) WO2020095010A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910092D0 (en) * 2019-07-15 2019-08-28 Balticgruppen Bio Ab New formulations
US11691954B2 (en) 2019-10-18 2023-07-04 Betagenon Ab Formulations
GB201915094D0 (en) * 2019-10-18 2019-12-04 Balticgruppen Bio Ab New formulations
GB202015585D0 (en) * 2020-10-01 2020-11-18 Betagenon Bio Ab New compounds
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods
CN113117241B (zh) * 2021-04-15 2022-01-28 中国科学院合肥物质科学研究院 一种提高胰岛素水平和敏感性的磁场发生装置及其应用
WO2025017194A1 (en) * 2023-07-20 2025-01-23 Betagenon Ab Methods for regulating blood glucose levels using a dual ampk activator and mitochondrial uncoupler

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2896397T (lt) 2003-08-01 2017-11-27 Mitsubishi Tanabe Pharma Corporation Nauji junginiai, turintys inhibitorinį aktyvumą prieš nuo natrio priklausomą gliukozės transporterį
EP1706108A4 (en) 2003-12-30 2009-08-12 Md Bioalpha Co Ltd TREATMENT OF FAT AND METABOLIC SYNDROME WITH TRANSHINONE DERIVATIVES FOR INCREASING METABOLISM ACTIVITY
WO2010051176A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2010270030B2 (en) * 2009-07-08 2015-12-24 Baltic Bio Ab 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer
EP3050567B1 (en) 2013-09-26 2020-11-04 Energenesis Biomedical Co., Ltd. Compound for activating ampk and uses thereof
KR101986983B1 (ko) 2015-01-07 2019-06-07 창저우 더저 메디컬 사이언스 컴퍼니.,리미티드 망기페린-6-ｏ-베르베린염 수화물 및 그 제조방법과 용도
AU2017205795A1 (en) 2016-01-05 2018-07-05 Nrl Pharma, Inc. Ascochlorin derivative and use thereof as AMPK activator

Similar Documents

Publication Publication Date Title
JP2023116697A5 (https=)
JP2024133474A5 (https=)
JP2021098728A5 (https=)
JP2022022264A5 (https=)
JP2009542702A5 (https=)
JP2009542699A5 (https=)
HRP20240995T1 (hr) Uporaba pimobendana za smanjenje veličine srca i odgodu početka kliničkih simptoma kod pacijenata s asimptomatičnim zatajenjem srca uslijed bolesti mitralnog zaliska
JP2013509411A5 (https=)
JP2019533660A5 (https=)
JP2021502392A5 (https=)
JP2021169534A5 (https=)
JP2019508476A5 (https=)
EP4494701A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2015508765A5 (https=)
JP2012525358A5 (https=)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
RU2006101061A (ru) Азенапин для лечения шизофрении у пациентов с избыточной массой тела или предрасположенностью к избыточной массе тела
CN111467348A (zh) 一种n-(噻唑-2-基)-3-(哌嗪-1-基)丙酰胺类衍生物在药物制备中的应用
WO2004017973A1 (ja) 統合失調症治療剤
Taylor et al. Association between Stevens-Johnson syndrome and benoxaprofen
JP2021525758A5 (https=)
FI3519050T3 (fi) Koostumuksia silmätautien hoitamiseksi
RU2014150946A (ru) Способ снижения веса
JPWO2023163203A5 (https=)
JP2021532165A5 (https=)